The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.

Cellular Biomedicine Group

Status and phase

Unknown

Early Phase 1

Conditions

Gastric Cancer.

Treatments

Biological: Autologous T cells-Based Immunotherapy

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT02704299

CBMG-TCM-GC-1.1

Details and patient eligibility

About

Evaluate the feasibility ,safety and efficacy of Surgery，Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.

Full description

Safety:AE/SAE Efficacy:immunologic function;FPS

Enrollment

36 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged between 18 to 80 years, males and females.
Subjects who understand and sign the consent form for this study.
The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes.
Subjects are surgical candidates.
No distant metastasis (M0) and No distant lymph node metastasis.
Expected survival time of at least 6 months.

Exclusion criteria

Subjects who do not sign the consent form for this study.
The subject has an allergic history of medicine or food.
The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system.
The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases.
The subject has an history of other malignant tumour.
The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial.
The subject has participated in any other clinical trial in the 3 months prior to this trial.
The subject is pregnant, lactating or planning to conceive within the next 24 months.
The subject has any other unsuitable or adverse condition to be determined by the investigator.